FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to anti-cancer peptide agents based on an endostatin fragment, and can be used in medicine in treating prostate cancer. Peptide is obtained by fusion of hexapeptide RGDRGD with section NH2-end of the endostatin (from 1 to 24 amino acid residues).
EFFECT: use of the invention provides anti-migratory and anti-invasive effect on prostate cancer as a result of antagonism with αv integrating receptors, suppressing FAK phosphorylation and reducing expression of MMP-7 and MMP-9 in tumor cells.
1 cl, 12 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| POLYPEPTIDE FOR INHIBITING MIGRATION AND INVASION OF SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY | 2018 |
|
RU2705547C1 |
| VERSIONS OF DISINTEGRIN AND THEIR PHARMACEUTICAL APPLICATION | 2015 |
|
RU2685869C1 |
| METHODS AND COMPOSITIONS USED FOR INHIBITING ANGIOGENESIS | 1997 |
|
RU2194528C2 |
| TECHNIQUES AND COMPOSITIONS USED TO INHIBIT αβ-CAUSED ANGIOGENESIS | 1997 |
|
RU2195312C2 |
| αvβ3 SELECTIVE POLYPEPTIDE, METHOD FOR PREPARING IT, POLYNUCLEOTIDE CODING IT, COMPOSITION CONTAINING SAID PEPTIDE, AND METHOD FOR TREATING AND PREVENTING | 2007 |
|
RU2477727C2 |
| USE OF CD 151 ANTIBODIES FOR TREATING CANCER | 2007 |
|
RU2464041C2 |
| αvβ3 INTEGRIN SELECTIVE POLYPEPTIDES CONJUGATED WITH VARIANT OF HUMAN SERUM ALBUMIN (HSA), AND THEIR PHARMACEUTICAL APPLICATIONS | 2010 |
|
RU2547592C2 |
| AXL SIGNALLING INHIBITION IN ANTIMETASTATIC THERAPY | 2011 |
|
RU2556822C2 |
| RECOMBINANT HYBRID INHIBITOR OF ANGIOGENESIS, AND ITS PRODUCTION METHOD | 2012 |
|
RU2499802C1 |
| NOVEL TUMOUR BIOMARKER | 2010 |
|
RU2567005C2 |
